CF PharmTech Statistics
Total Valuation
CF PharmTech has a market cap or net worth of HKD 9.24 billion. The enterprise value is 8.67 billion.
| Market Cap | 9.24B |
| Enterprise Value | 8.67B |
Important Dates
The last earnings date was Monday, March 30, 2026.
| Earnings Date | Mar 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CF PharmTech has 411.35 million shares outstanding. The number of shares has increased by 1.85% in one year.
| Current Share Class | 301.59M |
| Shares Outstanding | 411.35M |
| Shares Change (YoY) | +1.85% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.41% |
| Owned by Institutions (%) | 49.33% |
| Float | 187.13M |
Valuation Ratios
The trailing PE ratio is 3,340.95.
| PE Ratio | 3,340.95 |
| Forward PE | n/a |
| PS Ratio | 19.20 |
| PB Ratio | 5.65 |
| P/TBV Ratio | 6.32 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 3,135.46 |
| EV / Sales | 18.01 |
| EV / EBITDA | 233.45 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.59, with a Debt / Equity ratio of 0.10.
| Current Ratio | 4.59 |
| Quick Ratio | 4.23 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | 4.34 |
| Debt / FCF | n/a |
| Interest Coverage | -7.93 |
Financial Efficiency
Return on equity (ROE) is 0.21% and return on invested capital (ROIC) is -0.96%.
| Return on Equity (ROE) | 0.21% |
| Return on Assets (ROA) | -0.83% |
| Return on Invested Capital (ROIC) | -0.96% |
| Return on Capital Employed (ROCE) | -1.27% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 795,560 |
| Profits Per Employee | 4,571 |
| Employee Count | 605 |
| Asset Turnover | 0.28 |
| Inventory Turnover | 2.49 |
Taxes
| Income Tax | -17.68M |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 27.58 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 39.60 |
| Average Volume (20 Days) | 642,830 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CF PharmTech had revenue of HKD 481.31 million and earned 2.77 million in profits. Earnings per share was 0.01.
| Revenue | 481.31M |
| Gross Profit | 364.93M |
| Operating Income | -22.42M |
| Pretax Income | -14.92M |
| Net Income | 2.77M |
| EBITDA | 37.33M |
| EBIT | -22.42M |
| Earnings Per Share (EPS) | 0.01 |
Balance Sheet
The company has 730.25 million in cash and 161.98 million in debt, with a net cash position of 568.27 million or 1.38 per share.
| Cash & Cash Equivalents | 730.25M |
| Total Debt | 161.98M |
| Net Cash | 568.27M |
| Net Cash Per Share | 1.38 |
| Equity (Book Value) | 1.63B |
| Book Value Per Share | 3.97 |
| Working Capital | 774.73M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 61.60M |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 75.82%, with operating and profit margins of -4.66% and 0.57%.
| Gross Margin | 75.82% |
| Operating Margin | -4.66% |
| Pretax Margin | -3.10% |
| Profit Margin | 0.57% |
| EBITDA Margin | 7.76% |
| EBIT Margin | -4.66% |
| FCF Margin | n/a |
Dividends & Yields
CF PharmTech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.85% |
| Shareholder Yield | -1.85% |
| Earnings Yield | 0.03% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |